Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy heterosexual males between the ages of 16 years and 23 years and 364 days. Healthy men having sex with men (MSM) between the ages of 16 years and 26 years and 364 days.~* No clinical evidence of genital lesions suggesting sexually-transmitted disease, and no history of anogenital warts~* Additional criteria will be discussed with you by the physician~Exclusion Criteria:~* Concurrently enrolled in a clinical study involving collection of genital specimens~* History of known prior vaccination with an HPV vaccine~* Received an inactivated vaccine within 14 days or a live virus vaccine within 21 days prior to enrollment~* History of a severe allergic reaction that required medical intervention~* Received any immune globulin or blood-derived products within 6 months prior to the first study injection~* History of splenectomy, immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed with HIV infection~* Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections~* History of recent or ongoing alcohol or drug abuse

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine (Type: EXPERIMENTAL): The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
- Placebo (Type: PLACEBO_COMPARATOR): The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).